Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10153397 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL12251323 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL171770 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL12888936 | 0.77 | MAPT (0.38) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL12889010 | 0.77 | MAPT (0.38) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL17227576 | 0.74 | SMN1; SMN2 (0.42) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL20670512 | 0.74 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL12905011 | 0.73 | MAPT (0.41) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL8230056 | 0.73 | SMN1; SMN2 (0.47) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL12888984 | 0.72 | MAPT (0.40) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569512-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120015052-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015052-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | SMN1; SMN2 1758/4885MAPT 4011/4885CYP2C9 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.